A human abuse liability program for KP511

Trial Profile

A human abuse liability program for KP511

Planning
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2017

At a glance

  • Drugs Asalhydromorphone (Primary)
  • Indications Acute pain
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Most Recent Events

    • 28 Jun 2017 According to a KemPharm media release, the company anticipates initiating this program in the second half of 2017. Data expected in the second half of 2017.
    • 14 Sep 2016 New trial record
    • 10 Aug 2016 According to a KemPharm media release, the company anticipates initiating the KP511/ER human abuse liability program prior to the end of 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top